Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
et al., Nature, doi:10.1038/s41467-021-22446-z (meta analysis)
Meta analysis assigning 89% weight to the RECOVERY and SOLIDARITY trials, producing the same result. These trials used excessively high non-patient-customized dosage in very sick late stage patients, results are not generalizable to typical dosage or earlier treatment.For CQ, this study assigns 97% weight to Borba et al., however this study does not have a control group, comparing two different dosages of CQ.Of the 29 early treatment trials (including 6 RCTs), authors include the results of only one where they include a non-hospitalized death.Currently there are
38 HCQ
for COVID-19 early treatment studies, showing 72% [54‑83%] lower mortality and 41% [28‑52%] lower hospitalization.
Axfors et al., 9/18/2020, peer-reviewed, 97 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.